Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 14/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 13/20 | 0.53 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3106532 | 1.00 | ALOX5 (0.53) | ALOX5EPHX2KCNT1DRD2DRD1 | |
| SCHEMBL27630291 | 0.90 | EPHX2 (0.50) | ALOX5EPHX2KCNT1HDAC6ABCB1 | |
| SCHEMBL3106521 | 0.87 | ALOX5 (0.52) | ALOX5EPHX2KCNT1HDAC6 | |
| SCHEMBL3095366 | 0.86 | EPHX2 (0.56) | ALOX5EPHX2KCNT1 | |
| SCHEMBL27650413 | 0.86 | ALOX5 (0.48) | ALOX5EPHX2KCNT1HDAC6 | |
| SCHEMBL3099601 | 0.86 | CYP2D6 (0.47) | ALOX5EPHX2KCNT1 | |
| SCHEMBL30795509 | 0.86 | CYP2D6 (0.47) | ALOX5EPHX2KCNT1 | |
| SCHEMBL30795585 | 0.85 | EPHX2 (0.46) | ALOX5EPHX2KCNT1HDAC6 | |
| SCHEMBL3111438 | 0.85 | EPHX2 (0.46) | ALOX5EPHX2KCNT1HDAC6 | |
| SCHEMBL3099881 | 0.85 | ALOX5 (0.49) | ALOX5EPHX2KCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |